Literature DB >> 17632661

Absence of cardiac side effects during treatment of schizophrenia with risperidone in a patient with wolff-Parkinson-white syndrome.

Fabrice Bon1, Eric Louis Constant, Peter Goethals, Daniel Neu.   

Abstract

Entities:  

Year:  2007        PMID: 17632661      PMCID: PMC1911184          DOI: 10.4088/pcc.v09n0311d

Source DB:  PubMed          Journal:  Prim Care Companion J Clin Psychiatry        ISSN: 1523-5998


× No keyword cloud information.
  4 in total

1.  Olanzapine-induced QTc prolongation in a patient with Wolff-Parkinson-White syndrome.

Authors:  Kuan-Pin Su; Hsien-Yuan Lane; Chiao-Lin Chuang; Kun-Po Chen; Winston W Shen
Journal:  Schizophr Res       Date:  2004-02-01       Impact factor: 4.939

Review 2.  [Antipsychotic drugs and cardiovascular safety: current studies of prolonged QT interval and risk of ventricular arrhythmia].

Authors:  C Gury; O Canceil; P Iaria
Journal:  Encephale       Date:  2000 Nov-Dec       Impact factor: 1.291

Review 3.  Schizophrenia, antipsychotic drugs, and cardiovascular disease.

Authors:  Alexander H Glassman
Journal:  J Clin Psychiatry       Date:  2005       Impact factor: 4.384

4.  New Generation Antipsychotic Drugs and QTc Interval Prolongation.

Authors:  W VictorR Vieweg
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2003-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.